Publication details

Léčba Waldenströmovy makroglobulinémie

Title in English Treatment of Waldenström’s macroglobulinemia
Authors

ADAM Zdeněk KREJČÍ Marta POUR Luděk

Year of publication 2017
Type Article in Periodical
Magazine / Source Postgraduální medicína
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords Waldenström’s macroglobulinemia; treatment; rituximab; bortezomib; immunomodulatory drugs
Description Treatment of Waldenström’s macroglobulinemia is indicated in the symptomatic disease (significant organomegalia, B-symptoms, signs of hyperviscosity or cytopenia). Today, the combination of rituximab, cyclophosfamid and dexametasone (RCD) is recommended as the first-line treatment together with a more toxic classic alternative R-CHOP (rituximab, cyclophosfamid, doxorubicine, vincristine and prednisolon). From the recently introduced drugs bendamustin, bortezomib and immunomodulatory drugs standardly used in the treatment of multiple myeloma (lenalidomide or carfilzomib) have the role in the first- or subsequent lines. Recent studies showed the evidence of significant efficacy of ibrutinib. In relapsed patients autologous peripheral stem cell transplantation continues to be used routinely.

You are running an old browser version. We recommend updating your browser to its latest version.

More info